Lungs News and Research

RSS

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy and radiosurgery, will showcase its technology at two medical events in Asia during the month of March:

18 Mar 2010

Molecular basis of detecting tissue-damaging chemicals goes back more than 500 million years

Whenever you choke on acrid cigarette smoke, feel like you're burning up from a mouthful of wasabi-laced sushi, or cry while cutting raw onions and garlic, your response is being triggered by a primordial chemical sensor conserved across some 500 million years of animal evolution, report Brandeis University scientists in a study in Nature this week.

18 Mar 2010

Low vitamin D levels in African American children connected with high asthma rates

Researchers at Children's National Medical Center have discovered that African American children with asthma in metropolitan Washington, DC, are significantly more likely to have low levels of vitamin D than healthy African American children.

18 Mar 2010

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.

18 Mar 2010

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

18 Mar 2010

Cryotherapy may become the future treatment for cancer

Cryotherapy, an interventional radiology treatment to freeze cancer tumors, may become the treatment of the future for cancer that has metastasized in soft tissues (such as ovarian cancer) and in bone tumors.

18 Mar 2010

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

18 Mar 2010

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Researchers in Australia have demonstrated that blocking a certain protein can reduce or prevent cigarette smoke-induced lung inflammation in mice. Inflammation underlies the disease process of chronic obstructive pulmonary disease (COPD) and many other smoking-related ailments.

18 Mar 2010

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today announced that it has entered into agreements with a syndicate of institutional investors for up to $2.0 million. LifeTech Capital, a division of Aurora Capital LLC, acted as the exclusive placement agent for the financing.

17 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

SBRT improves survival in patients with inoperable non-small cell lung cancer

17 Mar 2010

SBRT may improve survival rates for lung-cancer patients: Study

A radiation therapy that uses multiple radiation beams to target tumors precisely has been shown to eliminate the primary tumor and ultimately may improve survival rates for lung-cancer patients unable to undergo surgery, according to UT Southwestern Medical Center physicians who led a national clinical trial of the treatment.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology 59th annual scientific session (ACC.10) in Atlanta. Their research includes data showing that the World Trade Center collapse has caused potentially dangerous heart problems in responders on-site.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Colon cancer patients often not treated with recommended level of chemotherapy

New results from a major initiative on the quality of cancer care in the United States show that patients with a common type of colon cancer -- especially older patients -- often are not treated as aggressively with chemotherapy as research shows is necessary to improve survival.

17 Mar 2010

NCCN Guidelines translated into Japanese

The NCCN Clinical Practice Guidelines in Oncology have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online.

17 Mar 2010

Bench to Bassinet Program aims to move lab results into clinical practice

To help speed the translation of scientific discoveries into usable treatments in congenital heart disease, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health launched the Bench to Bassinet Program.

17 Mar 2010

Lungs News and Research

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

Molecular basis of detecting tissue-damaging chemicals goes back more than 500 million years

Low vitamin D levels in African American children connected with high asthma rates

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

Cryotherapy may become the future treatment for cancer

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

SBRT improves survival in patients with inoperable non-small cell lung cancer

SBRT may improve survival rates for lung-cancer patients: Study

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Colon cancer patients often not treated with recommended level of chemotherapy

NCCN Guidelines translated into Japanese

Bench to Bassinet Program aims to move lab results into clinical practice

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News